TY  - GEN
N2  - This edited work presents a series of reviews focusing on Druggable Lipid Signaling Pathways. It enables researchers in both academic institutions and industry as well as physicians to understand historical aspects of lipid signaling and future directions of drug discovery targeting lipid signaling pathways. This book provides 9 pathways including acyltransferases, prostanoids, leukotrienes, epoxy fatty acids, sphingolipids, lysophospholipids, endocannabinoids, phosphoinositides, and lipid GPCRs. Readers will discover the importance of each lipid signaling pathway that contributes to broad range of diseases including neurological and neuropsychiatric diseases, pain, metabolic syndromes, cardiovascular diseases, cancer, dermatological diseases, fibrosis, inflammation, etc. Also, readers will recognize that many drugs targeting lipid signaling have been clinically used. Drugs currently under development are also discussed in each chapter, which includes some information about clinical trials and strategic drug designs.
DO  - 10.1007/978-3-030-50621-6
DO  - doi
AB  - This edited work presents a series of reviews focusing on Druggable Lipid Signaling Pathways. It enables researchers in both academic institutions and industry as well as physicians to understand historical aspects of lipid signaling and future directions of drug discovery targeting lipid signaling pathways. This book provides 9 pathways including acyltransferases, prostanoids, leukotrienes, epoxy fatty acids, sphingolipids, lysophospholipids, endocannabinoids, phosphoinositides, and lipid GPCRs. Readers will discover the importance of each lipid signaling pathway that contributes to broad range of diseases including neurological and neuropsychiatric diseases, pain, metabolic syndromes, cardiovascular diseases, cancer, dermatological diseases, fibrosis, inflammation, etc. Also, readers will recognize that many drugs targeting lipid signaling have been clinically used. Drugs currently under development are also discussed in each chapter, which includes some information about clinical trials and strategic drug designs.
T1  - Druggable lipid signaling pathways /
DA  - 2020.
CY  - Cham, Switzerland :
AU  - Kihara, Yasuyuki.
VL  - v.1274
CN  - QP751
CN  - QH506
PB  - Springer,
PP  - Cham, Switzerland :
PY  - 2020.
N1  - Includes index.
ID  - 943849
KW  - Lipids.
KW  - Cellular signal transduction.
KW  - Pharmacology.
KW  - Molecular biology.
KW  - Diagnosis, Laboratory.
KW  - Human genetics.
KW  - Cancer
SN  - 9783030506216
SN  - 3030506215
TI  - Druggable lipid signaling pathways /
LK  - https://univsouthin.idm.oclc.org/login?url=https://dx.doi.org/10.1007/978-3-030-50621-6
UR  - https://univsouthin.idm.oclc.org/login?url=https://dx.doi.org/10.1007/978-3-030-50621-6
ER  -